Adam W. Levin

Adam W. Levin

Auto-generated profile, based on publicly available information

Adam W. Levin

The Ohio State University

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ALAdam W. Levin
Adam W. Levin
RLRafaelle Lancelotta
Rafaelle Lancelotta
NSNathan D. Sepeda
Nathan D. Sepeda
NGNatalie Gukasyan
Natalie Gukasyan
SNSandeep Nayak
Sandeep Nayak
ADAlan K. Davis
Alan K. Davis
We examined if the therapeutic alliance between study participants and intervention facilitators in a psilocybin-assisted therapy (PAT) trial changed over time and whether there were relationships between alliance, acute psilocybin experiences, and depression outcomes. In a randomized, waiting list-controlled clinical trial for major depressive disorder in adults (N = 24), participants were randomized to an immediate (N = 13) or delayed (N = 11) condition with two oral doses of psilocybin (20mg/70kg and 30mg/70kg). Ratings of therapeutic alliance significantly increased from the final preparation session to one-week post-intervention (p = .03, d = .43). A stronger total alliance at the final preparation session predicted depression scores at 4 weeks (r = -.65, p = .002), 6 months (r = -.47, p = .036), and 12 months (r = -.54, p = .014) post-intervention. A stronger total alliance in the final preparation session was correlated with higher peak ratings of mystical experiences (r = .49, p = .027) and psychological insight (r = .52, p = .040), and peak ratings of mystical experience and psychological insight were correlated with depression scores at 4 weeks (r = -.45, p = .030 for mystical; r = -.75, p < .001 for insight). Stronger total alliance one week after the final psilocybin session predicted depression scores at 4 weeks (r = -.85, p < .001), 3 months (r = -.52, p = .010), 6 months (r = -.77, p < .001), and 12 months (r = -.61, p = .001) post-intervention. These findings highlight the importance of the therapeutic relationship in PAT. Future research should explore therapist and participant characteristics which maximize the therapeutic alliance and evaluate its relationship to treatment outcomes. Trial registration: Registration: Clinicaltrials.gov NCT03181529. https://classic.clinicaltrials.gov/ct2/show/NCT03181529.

11 August 2022 in International Journal of Drug Policy
Verified
Journal Article
Closed access
ALAdam Levin
Adam Levin
PNPaul B Nagib
Paul B Nagib
SDSelina Deiparine
Selina Deiparine
TGThomas Gao
Thomas Gao
JMJustin Mitchell
Justin Mitchell
ADAlan K Davis
Alan K Davis

13 September 2023 in Psychedelic Medicine
Verified
Journal Article
Closed access
ZHZachary Herrmann
Zachary Herrmann
ALAdam W. Levin
Adam W. Levin
SCSteven P. Cole
Steven P. Cole
SSSarah Slabaugh
Sarah Slabaugh
BMBrian Barnett MD
Brian Barnett MD
SJSaundra Jain
Saundra Jain
Mental health problems including depression, anxiety, suicide, and burnout are common among health care providers. Resilience and well-being are factors thought to protect against these incidents. Clinical trials and naturalistic studies of psychedelic compounds have shown decreases in depression, anxiety, and suicidality while suggesting improvements in well-being. This secondary analysis of a large cross-sectional online survey consisting of participants with at least one lifetime psychedelic use sought to examine how use affects health care providers who treat psychiatric disorders with medications. In total, 228 respondents retrospectively completed measures of depression, anxiety, and well-being before and after psychedelic exposure. They also reported lifetime use, harms attributed to use, and preferred psychedelic agent. Psychedelic use was associated with improvements in depression, anxiety, and well-being. Reported suicidality decreased and resilience increased. A factor analysis suggested that a cluster of mystical, interpersonal, and personal items predicted improvement in depression, anxiety, well-being, suicidality, and resilience. Preferred psychedelic agent did not affect outcomes. Frequency of use was not associated with outcomes although differences in effect sizes were seen. Harm reported was consistent with the general population, with 13.2% ( n = 30) reporting at least one harm. Pre-exposure alcohol use, aggressive impulses, and desire to die by suicide improved most often while marijuana use most often worsened or did not change. These results are consistent with clinical trials and naturalistic studies examining psychedelic use in the general population and suggest that health care providers who treat psychiatric disorders with medications may benefit from psychedelic use, although some harm was reported. Given the current mental health crisis among health care providers, further research is warranted to examine whether interventions utilizing psychedelics could improve well-being and effectiveness of health care providers while decreasing adverse mental health outcomes associated with working in health care. ClinicalTrials.gov (ID: NCT04040582).

20 December 2024 in Journal of Psychopharmacology
Verified
Journal Article
Closed access
ALAdam W Levin
Adam W Levin
Current models of psychedelic action in the brain propose changes along the dorsal–ventral and anterior–posterior axes but neglect to address the lateral axis. This article proposes a novel model of psychedelic action called HEALS (Hemispheric Annealing and Lateralization Under Psychedelics) which involves the reversal of the typical hierarchical relationship between the two hemispheres of the brain. In typical modes of consciousness, the hemispheres act in parallel process with the left predominating. Under psychedelics, as well as in other altered states of consciousness (ASCs), this hierarchy is reversed, with the right hemisphere released from inhibition by the left. In support of this model, the available neuroimaging evidence for lateralization under psychedelics is reviewed. Then, various cognitive and emotional changes observed under psychedelics are contrasted with those same functions in each hemisphere. These include attention; social and emotional intelligence; creativity and insight; and language. The article concludes with a review of laterality in other ASCs, such as meditative and trance states, and suggests that many phenomena associated with psychedelics, and other ASCs, might be explained by an atypical annealing between the hemispheres toward right hemisphere predominance.

4 May 2025 in Expert Review of Clinical Pharmacology
Verified
Journal Article
Open access
VAVictor Pablo Acero
Victor Pablo Acero
TFTaylor A. Flatt
Taylor A. Flatt
PGPeter M. Gooch
Peter M. Gooch
SGSkylar J. Gaughan
Skylar J. Gaughan
ALAdam W. Levin
Adam W. Levin
ADAlan K. Davis
Alan K. Davis
Psychedelic compounds are emerging treatments for depression, capable of producing rapid and lasting symptom reduction after 1-2 administrations in the context of psychotherapy - a stark contrast to traditional antidepressants. Despite promising outcomes, the mechanisms underlying psychedelics' reported antidepressant effects remain poorly understood and are often framed in fragmented ways. Clarifying these mechanisms is crucial for guiding future research and clinical innovation with psychedelics. This review critically examines current evidence on the mechanisms by which psychedelics may exert antidepressant effects. We highlight key mechanisms of action within biological, psychological, social, and spiritual domains that we believe are among the most compelling and deserving of further investigation. Throughout, we compare these mechanisms to those proposed for traditional antidepressants, identifying points of overlap and divergence. Although mechanistic research is valuable, an overemphasis on identifying discrete pathways may limit psychedelic science. Psychedelics likely work through complex, interwoven biological, psychological, and experiential processes that cannot be fully reduced to single mechanisms. Future research should move beyond frameworks and metrics used to validate conventional antidepressants to explore how suprapharmacological factors - set, setting, therapy modality, and integration - shape outcomes. Embracing this complexity is essential to realizing psychedelics' full therapeutic potential for depression.

30 July 2026 in Communications Medicine
Verified
Journal Article
Open access
SAStacey Armstrong
Stacey Armstrong
ALAdam W. Levin
Adam W. Levin
NSNathan D. Sepeda
Nathan D. Sepeda
HSHillary Shaub
Hillary Shaub
THTaweh Hunter
Taweh Hunter
ADAlan K. Davis
Alan K. Davis